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ABSTRACT
The coronavirus disease of 2019 (COVID-19) is a current pandemic of viral 
infection which mainly involves respiratory system and may progress 
into severe multiple organ dysfunction and mortality. Pulmonary 
artery hypertension (PAH) is a disease marked by increased mean 
pulmonary artery pressure and pulmonary vascular resistance due to 
pulmonary panvascular remodeling. Although rare, the prevalence of 
PAH is currently escalating in Indonesia due to increased diagnostic 
capacity and referral, treatment availability and improved survival. 
Despite chronic cardiac and pulmonary diseases are at increased risk 
to develop severe COVID-19, patients with PAH are considered to be 
not in higher risk to develop severe COVID-19. However, whether this 
population is protected from severe COVID-19 is unclear. There are 
protective and offensive factors need to be considered in PAH patients 
in respect to COVID-19. 
ABSTRAK
Penyakit koronavirus 2019 (COVID-19) menjadi infeksi virus pandemik 
yang terutama melibatkan sistem pernapasan dan dapat menjadi 
pemberatan menuju disfungsi organ multipel yang berat dan kematian. 
Hipertensi arteri paru (HAP) merupakan penyakit yang ditandai dengan 
kenaikan tekanan rerata arteri paru dan tahanan pembuluh darah paru 
karena remodeling seluruh lapisan pembuluh darah paru. Meskipun 
jarang, prevalensi HAP saat ini meningkat di Indonesia akibat kenaikan 
kemampuan diagnosis dan rujukan, ketersediaan obat dan perbaikan 
angka kesintasan. Meskipun penyakit jantung dan paru kronik 
mempunyai peningkatan risiko menjadi COVID-19 yang berat, pasien 
HAP dipertimbangkan tidak mempunyai risiko lebih tinggi mengalami 
COVID-19 yang berat. Namun, apakah populasi ini terlindungi dari 
COVID-19 yang berat masih belum jelas. Terdapat faktor-faktor 
perlindungan dan pemberatan yang perlu dipertimbangkan pada 
pasien PAH sehubungan dengan COVID-19. 
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INTRODUCTION
The coronavirus disease of 2019 
(COVID-19) is a current pandemic of 
viral infection caused by severe acute 
respiratory syndrome coronavirus 2 
(SARS-CoV2).1 The COVID-19 is mainly 
attacking respiratory system and may 
progress into severe multiple organ 
dysfunction.1 Patients with predisposing 
chronic pulmonary and cardiovascular 
diseases are at increased risk for 
serious adverse outcomes from the 
COVID-19.2 The meta-analysis revealed 
that elderly, hypertension, diabetes 
mellitus, chronic obstructive pulmonary 
disease, cardiovascular disease, and 
cerebrovascular disease are the major 
risk factors for increased severity of 
COVID-19.3 The complications that occurs 
are acute coronary syndrome, cardiac 
arrest, myocarditis, cardiomyopathy, 
venous thromboembolism, pulmonary 
embolism, acute lung edema, arrhythmia 
and acute respiratory distress 
syndrome.4,5
Patients with pulmonary artery 
hypertension (PAH), a condition marked 
by increased mean pulmonary artery 
pressure and pulmonary vascular 
resistance without increased in 
pulmonary artery wedge pressure, 
have similar chance to get infected 
by SARS-CoV2as other population.6 
Although the prevalence of PAH in 
Indonesia and worldwide is not high 
(ranging from 5-52 cases/million adults 
worldwide),7 as compared with other 
common cardiovascular and pulmonary 
diseases, it has increasing attention 
due to availability of medication, good 
referral system and improved survival. 
In Indonesia, the most common clinical 
type of PAH is congenital heart disease-
associated PAH (CHD-PAH), who is 
currently increasing in prevalence. At 
present, the patients association, Yayasan 
Hipertensi Paru Indonesia, and the 
cardiologist association for pulmonary 
hypertension, Working Group on 
Pulmonary Hypertension Indonesian 
Heart Association, have been actively 
registering patients suffered with PAH 
and working together to increase the 
awareness of PAH. Dr. Sardjito General 
Hospital, Yogyakarta is one of the PAH-
center in the region which has complete 
facility to diagnose and treat PAH 
patients. In the COVID-19 pandemic, 
the risk to develop COVID-19 and how 
severe it affects PAH patients need to 
be predicted. Whether this population 
is at increased risk to develop severe 
COVID-19 is unclear, especially due to 
limited literatures and case reports.
This literature review aims to 
provide the view of possible outcomes 
if patients with PAH and undergo PAH-
specific therapy get contracted by SARS-
CoV2 and develop COVID-19 and discuss 
the impact of protective and offensive 
factors based on current literatures. We 
searched the published literatures in 
PUBMED and MEDRXIV preprint server 
databases related to the topics of PAH, 
SARS-CoV2 and COVID-19. For further 
elaboration, we searched published 
literatures relevant to topics of PAH, 
viral infection and pathophysiology to 
support our view.
DISCUSSION
Pulmonary artery hypertension 
during COVID-19 pandemic
Patients with COVID-19 usually 
have symptoms of respiratory diseases, 
i.e. fever, dry cough, and  shortness 
of breath.4,5 In patients with PAH, 
every complaint associated with 
aforementioned symptoms should 
be suspected for having COVID-19. 
Therefore, the test to confirm the 
diagnosis of COVID-19 should be 
performed. Most patients who are 
hospitalized with confirmed COVID-19 
are diagnosed withpneumonia, which 
may progress to acute respiratory 
distress syndrome or sepsis due to severe 
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viral pneumonia or secondary bacterial 
infection.5
The non-specific symptoms and signs 
of infection, such as worsening right 
heart failure in PAH and desaturation 
due to abrupt increased of pulmonary 
artery pressure, may indicate the 
presence of underlying contagion.6 In 
addition to progression of PAH disease, 
in the COVID-19 pandemic era the 
physicians should make differential 
diagnosis with SARS-CoV2 infection or 
COVID-19. Especially, if deterioration of 
respiratory symptoms occurs, the test for 
COVID-19 must be performed.
Current reports from China, Italy 
and USA indicate that there are not so 
many patients with PAH get affected 
by COVID-19 infection who show 
deteriorating right ventricle function 
or pulmonary hypertension crises.6,8,9 
Most cases have mild diseases.8,9 Unlike 
chronic cardiovascular and pulmonary 
diseases, such as bronchial asthma, 
chronic obstructive pulmonary disease 
and coronary artery disease, so far PAH 
is not considered to be a risk factor to 
develop severe COVID-19.8 Some experts 
even estimate that PAH patients possess 
factors that reduce the inclination for 
severe COVID-19, despite the data is not 
yet sufficient to conclude the estimation 
and need more observation on this 
current pandemic.8,10
The factors that influence severity 
of COVID-19 in pulmonary artery 
hypertension
Despite the lack of current clinical 
data, there are some characteristics that 
probably had protective or offensive 
effects in patients with PAH against 
severe COVID-19 (FIGURE 1). 
The protective characteristics 
include demographic characteristics and 
pathobiology of PAH. The demographic 
characteristics which are deemed 
protective are 1) the younger age; 2) the 
female gender; and 3) the lower body 
mass index.
The younger age 
Most patients with PAH were at 
young age. These populations have 
fewer chances to have severe COVID-19 
disease. In our registry of adult with 
congenital heart disease and pulmonary 
hypertension (COHARD-PH registry) and 
primary PAH, the majority of patients 
was at age 30-50 years old.11 These 
populations have less risk to develop 
severe and complicated COVID-19. 
Older ages at > 65 years old are the 
most vulnerable populations to develop 
severe COVID-19.3,5
The female gender
Most PAH patients were females.7 
Female genders, especially at young 
ages, have associated with protective 
characteristics. Currently, there are no 
satisfying mechanism to explain the 
protective factor from severe COVID-19 
by being females, other than statistical 
and demographic finding.5 Several 
reports indicated that male patients had 
worst prognosis and preponderance to 
develop severe and complicated cases of 
COVID-19.3,5 Males were more prone to 
get serious COVID-19 than females.3,5
The lower body mass index
Lower body mass index is observed 
in patients with PAH, especially CHD-
associated PAH.7,11 The obesity is one 
of risk factors for developing severe 
COVID-19.  It is unclear why obese 
patients associate with worsened 
outcome if get COVID-19.5 Therefore, we 
suggest that lower body mass index or 
non-obese PAH patients have lower risk 
to obtain severe COVID-19.
Pathobiology of PAH has been 
recognized from both animal and 
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human studies. It mainly associates with 
pulmonary vascular remodeling, lung 
cellular modification and adaptation, 
and changing expression of proteins. 
The pathobiology of PAH characteristics 
which are deemed protective are 1) the 
remodeling of pulmonary vasculature; 
2) the changes of lymphocyte population; 
3) the reduced membrane-bound 
angotensin converting enzyme 2 (ACE2) 
expression;  4) the response to pulmonary 
vasodilators; 5) the chronic hypoxia 
condition; and 6) the determination of 
left heart function.
The remodeling of pulmonary 
vasculature
The pulmonary vasculopathy and 
vascular remodeling may response 
differently to exacerbation of 
inflammation seen in normal pulmonary 
vasculature. The altered pulmonary 
endothelia in PAH may have lessen 
capability to generate inflammatory 
response. Panvasculopathy, the 
vasculopathy of the intimal, medial and 
adventitial layers, in severe PAH may 
have a lack of response to endothelitis, 
panvasculitis and cytokine recruitment 
shown in patients with severe COVID-19.8 
Alterations in structure and function 
of the endothelia as well as neointimal, 
medial and adventitial layers remodeling 
(panvasculopathy) are frequently seen 
in PAH patients. 
The changes of lymphocyte population
The altered lymphocyte composition 
in the lung and blood of PAH patients 
have been recognized.8 The majority 
of lung tissue in PAH is dominated by 
an abnormally elevated number of the 
CD3+ and the CD8+ T cells. In the blood 
circulation, the CD4+ Treg dominates 
lymphocyte subtypes.12 The role of CD4+ 
Treg cells is to control self-tolerance 
and adaptation, which is altered in 
patients with PAH.12 Lymphopenia is 
marked of severe COVID-19, suggesting 
that SARS-CoV-2 can invade and 
damage lymphocytes.5 In COVID-19, 
reduced CD8+ T cells are independent 
predictor for disease severity due to 
their diminished cytotoxic immune 
activities.13 Abundance lung CD-8+ T cells 
in PAH may help expedite viral clearance 
by their cytotoxic immune properties.13
The reduced membrane-bound ACE2 
expression
The reduced ACE2 expressions in 
lung tissue have been recognized in PAH 
at both cellular membrane and soluble 
ACE2.14 It may be a protective factor in 
term of reduction of SARS-CoV2 entry 
to the cells.15 The ACE2 is a membrane-
bound cellular receptor for SARS-CoV2 
and an entry point for the virus into the 
host cells, especially in the respiratory 
tracts.15
The chronic use of pulmonary 
vasodilators (sildenafil and/or 
beraprost)
In Indonesia, the only medication 
currently available widely for 
PAH are sildenafil and beraprost.16 
Sildenafil is a phosphodiesterase-5 
(PDE5) inhibitor and beraprost is 
prostacyclin analog. These drugs are 
potent pulmonary vasodilators. These 
pulmonary vasodilators are thought to 
protect the lung from acute respiratory 
distress syndrome. Sildenafil itself 
may cause ventilation/perfusion (V/Q) 
mismatch in patients with underlying 
lung disease,17 however in PAH and 
chronic thromboembolic pulmonary 
hypertension it improve the V/Q 
mismatch. In COVID-19, the improved V/Q 
mismatch and pulmonary vasodilatation 
by sildenafil and beraprost make PAH 
patients avoid serious COVID-19 illness.17
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The chronic hypoxia state
The chronic hypoxia states in may 
inhibit the SARS-CoV2 growth, based on 
data from high altitude acclimatization 
environments.18 Influenza viruses are 
among viruses that oxygen dependent 
for growth and replication.19 The chronic 
hypoxia state and polycythemia in 
patients with CHD-associated PAH and 
Eisenmenger syndrome may inhibit 
virus replication. However, the behavior 
of SARS-CoV2 with reduced oxygen 
environments in CHD–associated PAH 
and severe PAH is unknown. However, 
based on the Adult Congenital Heart 
Disease Anatomy and Physiological 
Stage Classification, patients with 
CHD–associated PAH and Eisenmenger 
syndrome are considered at high risk 
for complications related to COVID-19 
infection, due to decreased functional 
reserve.20
The maintained left heart function
The majority of patients with PAH 
have good left heart function, which 
is indicated by preserved left ventricle 
ejection fraction. The current data 
indicate that those with left heart failure 
have increased risk to develop severe 
COVID-19 infection and complication.4,5 
However, the ventricle interdependency 
may become a deteriorating factor 
in COVID-19 infection which causes 
uncontrollable severe disease.
The offensive characteristics are 
more associated with pathobiology 
PAH characteristics.  The offensive 
characteristics of patients with PAH 
in response to COVID-19 are 1) the 
altered immune systems; 2) the reduced 
circulating ACE2 and angiotensin 1-7; 3) 
the increased of endothelin-1; 4) the right 
ventricular dysfunction; 5) the altered 
chemokine and cytokine productions; 
and 6) the different population of 
macrophage and neutrophils (FIGURE 1).
FIGURE 1. The protective or offensive factors in patients with 
PAH against severe COVID-19
100
J Med Sci, Volume 52, Number 3 (SI), 2020, Juli: 95-104
The altered immune system
The maladaptive of the immune 
response in PAH becomes one 
pathogenesis of pulmonary panvascular 
remodeling based on the accumulation 
of perivascular inflammatory cells and 
the large quantity of cytokines and 
chemokines production.21 During this 
process, a balance between immunity 
and tolerance is disrupted which result in 
chronic inflammation or autoimmunity 
disease.21 Whether the infection of 
SARS-CoV2 leads to harmful immune 
response in PAH, such as cytokine storm 
and aberrant immune reactivity, and 
severe COVID-19 development need to 
be observed and investigated.
The reduced circulating ACE2 and 
angiotensin 1-7
The PAH patients have declined 
circulating ACE2, ACE2 activity and 
angiotensin 1-7.14,22 The reduced 
circulating ACE2 associates with reduced 
neutralizing effect of soluble ACE2 
because of elimination ofits binding 
into the SARS-CoV2.22 The disruption 
of angiotensinII/ACE2/angiotensin 1-7 
axis in PAH conveys greater risk to 
have severe COVID-19 because it leads 
to exacerbation of viral activity and 
enhancement of angiotensin deleterious 
effects.22
The increased of endothelin-1
The PAH patients have increasing 
endothelin-1 level,  a potent 
vasocontrictor and pro-inflammatory 
peptide. Considerable lung damage in 
response to inflammation is recognized 
in COVID-19 and this is due to abundant 
necroptosis by SARS-CoV-2 cytopathic 
effect.23 Excess endothelin-1 in PAH 
activates necroptotic gene expression 
and during COVID-19 may exacerbate 
necroptotic pathways which give 
rise to the disastrous effects of the 
proinflammatory necroptotic cell death 
by SARS-CoV-2.23 Patients received 
endothelin A-receptor antagonist (ETa-
RA) to treat PAH may have protection 
from severe COVID-19 infection effect 
by inhibiting inflammatory response of 
endothelin-1 and restraining angiotensin 
II synergistically.7 Patients without ETa-
RA chronic medication do not obtain this 
speculative beneficial impact, but rather 
may get negative effects from excess of 
lung endothelin-1.
The right ventricular dysfunction
Right heart failure due to PAH is one 
great contributor of mortality in patients 
with PAH. Right heart failure is predictor 
of complication and mortality in patients 
with severe COVID-19 infection.6 Patients 
with PAH with worsened WHO class 
functional and signs of right heart failure 
may pose greater risk to develop severe 
COVID-19 infection and complication. 
However, based on prior publications 
evaluating the effects of acuteRHF 
superimposed on systemic infection, 
it is likely that RHF and concomitant 
COVID-19 will lead to increased mortality 
in the PAH patient.6
The altered chemokine and cytokine 
productions
In PAH, in addition to increased 
perivascular cells accumulation and 
intravascular infiltration, circulating 
levels of certain cytokines and 
chemokines are abnormally elevated.21 
These include interleukin (IL)-1β, IL-6, 
IL-8, monocyte chemoattractant protein 
(MCP)-1, fractalkine, CCL5/RANTES and 
tumor necrosis factor (TNF)-α.21 Some 
of these cytokines and chemokines 
correlate with a worse clinical outcome 
in PAH patients and may serve as 
biomarkers of disease progression. These 
biomarkers may relate with cytokine 
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storm in COVID-19 severe cases.
The different population of 
macrophages and neutrophils
In pulmonary environment of PAH, 
the enhanced macrophage recruitment 
in adventitial layer of pulmonary 
vasculature has been identified.21 
Activation of macrophages stimulates 
and induces proliferation of vascular 
fibroblasts. There is an altered metabolism 
by increased fatty acid oxidation 
and production of reactive oxygen 
species due to abnormal interaction of 
fibroblasts and macrophages.21 Elevated 
neutrophil elastase is also present in 
pulmonary artery smooth muscle cells 
of PAH patients.21 The propensity of 
inflammatory modulation by neutrophil 
elastase renders increased inflammatory 
response in COVID-19.
Current state of pulmonary artery 
hypertension affected by COVID-19
Currently, we do not receive the 
report of our patients get infected by 
SARS-CoV2 and confirmed COVID-19. The 
preliminary report from U.S.A indicate 
that 13 PAH patients confirmed with 
COVID-19, with three patients needed 
intubation (23.1%) and one patient 
died (7.7%).8 The report from China, 
indicated that during lock-down and 
home-quarantine imposed due to the 
pandemic the majority of PAH patients 
showed no much change of disease 
condition.9 They reported three patients 
hospitalized, two patients with heart 
failure and one patient with pneumonia. 
All three patients were finally died, one 
patient due to fall and two patients due 
to worsening PAH.9 The death seems do 
not correlate with COVID-19 infection.9
The best strategy to avoid COVID-19 
infection should also be implemented 
to patients with PAH, disregards its 
etiology.6,13 The current Indonesian 
government rules and advices such 
as social distancing, partial lock down 
and any measures should be obediently 
followed by patients and their families. 
In Indonesia, we have Yayasan Hipertensi 
Paru Indonesia (Indonesian Pulmonary 
Hypertension Foundation) where 
patients and families can communicate 
using social media, like whatsapp and 
facebook and helping eachother. They 
reported that no one hasdiagnose with 
the COVID-19 and had harmful outcome. 
The advocacy by Working Group on 
Pulmonary Hypertension, Indonesia 
Heart Association to make certain that 
patients’ needs are adequately provided 
is necessary. 
The medical personnel/doctors and 
hospitals should also perform necessary 
steps to ensure that patients with PAH have 
access to medication and consultation 
in this unprecedented situation in 
Indonesia. Currently the medication for 
PAH, i.e. sildenafil and beraprost could 
only be provided in certain hospitals. 
Therefore, some patients found difficulty 
to reach these hospitals for regular 
visit which is usually every month. The 
encouragement to continue medication 
is mandatory. An innovative approach 
should be conducted to care and monitor 
the patients, such as telemedicine and 
online consultation. Through these 
approaches, the patients can have 
opportunity to share and consult their 
condition to the expert especially in 
association with possible symptom of 
SARS-CoV2 infection. FIGURE 2 shows 
the necessary steps each stakeholders 
should perform in order to make sure 
PAH patients have optimal condition 
during current COVID-19 pandemic.
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FIGURE 2. The necessary steps each should be implemented in order to make sure 
PAH patients have optimal condition during current COVID-19 pandemic
CONCLUSION
Patients with PAH do not increase 
the risk for developing severe COVID-19. 
The possibility to get SARS-CoV2 infection 
is similar with general population and 
influenced by many factors. There are the 
protective and offensive characteristics 
that affect the outcome of COVID-19 
on patients with PAH. We assume that 
there are more protective factors that 
made the PAH-treated patients most 
likely protected from severe disease of 
COVID-19. However, the limited case 
reports, research’s papers and literatures 
in the topics render the limitation of 
this review. Further studies should be 
addressed to corroborate or contradict 
the hypothetical outlook of this review.
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